Entering text into the input field will update the search result below
Try for free
Search for Symbols, analysts, keywords

Mark Cuban online pharmacy to offer AbbVie Humira biosimilar

Jun. 01, 2023 9:23 AM ETAbbVie Inc. (ABBV), CHRSAMGNBy: Jonathan Block, SA News Editor15 Comments
Vanity Fair New Establishment Summit - Day 1

Matt Winkelmeyer/Getty Images Entertainment

  • Mark Cuban Cost Plus Drug Company will offer a biosimilar version of AbbVie's (NYSE:ABBV) Humira (adalimumab) manufactured by Coherus BioSciences (NASDAQ:CHRS) known as Yusimry starting in July.
  • Yusimry will cost $569.27 plus dispensing and shipping fees. It is the first biologic product offered by the service.
  • Cuban's online pharmacy was launched in January 2022 and offers more than 1K generic and brand prescription drugs.
  • The first Humira biosimilar, from Amgen (AMGN), entered the market in January.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.